Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.67 |
| ▸ | MMP1 | P03956 | 11/20 | 0.67 |
| ▸ | MMP2 | P08253 | 11/20 | 0.67 |
| ▸ | MMP9 | P14780 | 11/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25725313 | 0.89 | MMP1 (0.60) | EGFRMMP1MMP2MMP9NPC1 | |
| SCHEMBL25722354 | 0.84 | EGFR (0.75) | EGFRMMP1MMP2MMP9NPC1 | |
| SCHEMBL25722338 | 0.84 | NAMPT (0.58) | NPC1RAB9AKDM4E | |
| SCHEMBL25726003 | 0.83 | MMP1 (0.67) | EGFRMMP1MMP2MMP9NPC1 | |
| SCHEMBL25723203 | 0.83 | EGFR (0.67) | EGFRMMP1MMP2MMP9NPC1 | |
| N-(2-Chlorophenyl)Cinnamamide SCHEMBL9988230 | 0.80 | MMP1 (1.00) | EGFRMMP1MMP2MMP9NPC1 | |
| N-(2-Chlorophenyl)Cinnamamide SCHEMBL2683663 | 0.80 | MMP1 (1.00) | EGFRMMP1MMP2MMP9NPC1 | |
| SCHEMBL3228591 | 0.80 | EGFR (0.71) | EGFRMMP1MMP2MMP9MAOA | |
| SCHEMBL3228583 | 0.80 | EGFR (0.71) | EGFRMMP1MMP2MMP9MAOA | |
| N-(2-Chlorophenyl)Cinnamamide SCHEMBL3063601 | 0.80 | MMP1 (1.00) | EGFRMMP1MMP2MMP9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | SALL4, GLI2, GLI1 | EGFR 261/4885MMP1 4680/4885MMP2 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.